Diaceutics (LON:DXRX) Issues Earnings Results

Diaceutics (LON:DXRX) issued its quarterly earnings results on Tuesday. The company reported GBX (3.27) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Diaceutics had a net margin of 0.25% and a return on equity of 0.25%.

Diaceutics Trading Up 0.3%

DXRX stock opened at GBX 186.65 on Wednesday. Diaceutics has a one year low of GBX 125 and a one year high of GBX 190. The stock has a market cap of £158.39 million, a price-to-earnings ratio of 1,696.82 and a beta of 0.88. The company has a fifty day moving average price of GBX 145.97 and a two-hundred day moving average price of GBX 150.95. The company has a debt-to-equity ratio of 2.85, a current ratio of 3.43 and a quick ratio of 9.92.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group reaffirmed a “buy” rating and issued a GBX 215 target price on shares of Diaceutics in a research report on Tuesday. Two analysts have rated the stock with a Buy rating, According to MarketBeat.com, Diaceutics presently has a consensus rating of “Buy” and an average target price of GBX 215.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.